Clinically significant heart disease as evidenced by myocardial infarction, arterial thrombotic events in the past  months, severe or unstable angina, class III-IV New York Heart Association heart failure
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease or cardiac ejection fraction measurement of < % at baseline
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes), New York Heart Association (NYHA) class III-IV heart disease or cardiac ejection fraction measurement of < % at baseline
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease or cardiac ejection fraction measurement of <  % at baseline, if done
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease or cardiac ejection fraction measurement of <  % at baseline
Myocardial infarction or arterial thromboembolic events within  months prior to Baseline or severe or unstable angina, New York Heart Association (NYHA) Class III or IV disease, or a QTcB (corrected according to Bazett's formula) interval >  msec
Active co-morbidity, defined as follows:\r\n* Chronic liver disease with cirrhosis (Child-Pugh B or C) or active hepatitis B or C\r\n* History of pituitary or adrenal dysfunction\r\n* Poorly controlled diabetes mellitus (Ac > % or history of complications including peripheral neuropathy, end organ damage, hospitalization, amputation)\r\n* Poorly controlled glaucoma\r\n* Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association (NYHA) class III-IV heart disease or known cardiac ejection fraction measurement of < % at baseline\r\n* Clinical evidence of active infection of any type, including active or symptomatic viral hepatitis\r\n* Known immune deficiency and/or human immunodeficiency virus (HIV)-positive patients\r\n* Any medical condition that warrants long-term corticosteroid use in excess of study dose
clinically significant heart disease including but not limited to: myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or known cardiac ejection fraction measurement of <  %;
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association (NYHA) class III or IV heart disease or cardiac ejection fraction measurement of <  % at baseline
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association (NYHA) class III-IV heart disease or cardiac ejection fraction measurement of < % at baseline
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease or cardiac ejection fraction measurement of < % at baseline
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of < % at baseline
Myocardial infarction or arterial thromboembolic events within  months prior to baseline or severe or unstable angina, New York Heart Association (NYHA) class III or IV disease, or a corrected QT (QTc) interval >  msec
Myocardial infarction or arterial thromboembolic events within  months prior to baseline or severe or unstable angina, New York Heart Association (NYHA) class III or IV disease, or a corrected QT (QTc) interval >  msec
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, unstable atrial fibrillation, or New York Heart Association (NYHA) class III-IV heart disease
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease or known cardiac ejection fraction measurement of <  % at baseline
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease or cardiac ejection fraction measurement of <  % at baseline, if done
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association class III-IV heart disease or cardiac ejection fraction measurement of < % at baseline
Clinically significant heart disease as evidenced by myocardial infarction or arterial thrombotic event within the past  months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease or cardiac ejection fraction measurement of < % at baseline
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease or cardiac ejection fraction measurement of <  % at baseline
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association class III-IV heart disease or cardiac ejection fraction measurement of < %
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past  months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease or cardiac ejection fraction measurement of <  % at baseline
